Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL430650 | 0.88 | NR1H4 (0.50) | NR1H4HDAC10HDAC6 | |
| SCHEMBL20162273 | 0.88 | MEN1 (0.51) | NR1H4MAPT | |
| SCHEMBL6484837 | 0.86 | NR1H4 (0.46) | NR1H4MAPT | |
| SCHEMBL12869940 | 0.85 | NR1H4 (0.50) | NR1H4MAPT | |
| SCHEMBL20162270 | 0.84 | NR1H4 (0.56) | NR1H4MAPT | |
| SCHEMBL9061094 | 0.82 | NR1H4 (0.46) | NR1H4MAPT | |
| SCHEMBL6536139 | 0.82 | TP53 (0.53) | NR1H4GAAHDAC3HDAC4HDAC1 | |
| SCHEMBL12358376 | 0.81 | GAA (0.39) | GAAMAPTHDAC3HDAC4HDAC1 | |
| SCHEMBL12372703 | 0.81 | KDM4E (0.56) | GAAMAPT | |
| SCHEMBL13552273 | 0.81 | MAPT (0.56) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032787-A1 | Pheny (alkyl)carboxylic acid derivatives and dionic phenylalkylheterocyclic derivatives and their use as medicines with serum glucose and/or serum lipid lowering activity | SIGMA-TAU INDUSTRIES FARMACEUTICHE RIUNITE S.P.A. (IT) | 2005-02-10 | — | — | US | disclosed |
| WO-2004113266-A1 | DERIVATIVES OF PHENYLALKYL AND PHENOXYALKYL ACIDS FOR THE TREATMENT OF THE HYPERGLYCAEMIA AND HYPERTRIGLYCERIDAEMIA AND TYPE 2 DIABETES AND PROCESS FOR PREPARING THEM | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-12-29 | — | — | WO | disclosed |
| EP-1465858-A2 | PHENY(ALKYL)CARBOXYLIC ACID DERIVATIVES AND DIONIC PHENYLALKYLHETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDICINES WITH SERUM GLUCOSE AND/OR SERUM LIPID LOWERING ACTIVITY | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003059864-A2 | PHENY(ALKYL)CARBOXYLIC ACID DERIVATIVES AND DIONIC PHENYLALKYLHETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDICINES WITH SERUM GLUCOSE AND/OR SERUM LIPID LOWERING ACTIVITY | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032787-A1 | Pheny (alkyl)carboxylic acid derivatives and dionic phenylalkylheterocyclic derivatives and their use as medicines with serum glucose and/or serum lipid lowering activity | LIPC, CPT1A, GPR119 | NR1H4 367/4885GAA 318/4885MAPT 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.